Compare RGEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | HALO |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 12.0B |
| IPO Year | 1995 | 2001 |
| Metric | RGEN | HALO |
|---|---|---|
| Price | $173.46 | $107.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $167.67 | $78.64 |
| AVG Volume (30 Days) | 926.0K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | N/A |
| EPS | 0.24 | ★ 3.11 |
| Revenue | $141,236,000.00 | ★ $151,862,000.00 |
| Revenue This Year | $14.30 | $28.24 |
| Revenue Next Year | $14.52 | $12.56 |
| P/E Ratio | $723.38 | ★ $34.28 |
| Revenue Growth | ★ 35.10 | N/A |
| 52 Week Low | $100.99 | $61.23 |
| 52 Week High | $188.73 | $111.15 |
| Indicator | RGEN | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 59.60 |
| Support Level | $156.65 | $103.47 |
| Resistance Level | $175.32 | $111.15 |
| Average True Range (ATR) | 6.78 | 2.31 |
| MACD | -1.20 | -1.17 |
| Stochastic Oscillator | 56.81 | 40.89 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.